BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20522011)

  • 1. Transgenic mouse models of Parkinson's disease and Huntington's disease.
    Skaper SD; Giusti P
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):455-70. PubMed ID: 20522011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease.
    Thomas B; Beal MF
    Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R183-94. PubMed ID: 17911161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse models of Huntington's disease.
    Menalled LB; Chesselet MF
    Trends Pharmacol Sci; 2002 Jan; 23(1):32-9. PubMed ID: 11804649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular biology of Huntington's disease.
    Ho LW; Carmichael J; Swartz J; Wyttenbach A; Rankin J; Rubinsztein DC
    Psychol Med; 2001 Jan; 31(1):3-14. PubMed ID: 11200958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse Models of Huntington's Disease.
    Farshim PP; Bates GP
    Methods Mol Biol; 2018; 1780():97-120. PubMed ID: 29856016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knock-in mouse models of Huntington's disease.
    Menalled LB
    NeuroRx; 2005 Jul; 2(3):465-70. PubMed ID: 16389309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective neuronal degeneration in Huntington's disease.
    Cowan CM; Raymond LA
    Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
    Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
    PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
    Mo C; Renoir T; Hannan AJ
    Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington's disease.
    Mo C; Hannan AJ; Renoir T
    Neurosci Biobehav Rev; 2015 May; 52():178-92. PubMed ID: 25770041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
    Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
    Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
    Hannan AJ
    Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene.
    Ishiguro H; Yamada K; Sawada H; Nishii K; Ichino N; Sawada M; Kurosawa Y; Matsushita N; Kobayashi K; Goto J; Hashida H; Masuda N; Kanazawa I; Nagatsu T
    J Neurosci Res; 2001 Aug; 65(4):289-97. PubMed ID: 11494364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in Huntington's disease.
    Gutekunst CA; Norflus F; Hersch SM
    Curr Opin Neurol; 2000 Aug; 13(4):445-50. PubMed ID: 10970063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in Huntington's and Parkinson's Disease.
    O'Keeffe GC; Michell AW; Barker RA
    Ann N Y Acad Sci; 2009 Oct; 1180():97-110. PubMed ID: 19906264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in understanding the pathogenesis of Huntington's disease.
    Reddy PH; Williams M; Tagle DA
    Trends Neurosci; 1999 Jun; 22(6):248-55. PubMed ID: 10354600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
    Crocker SF; Costain WJ; Robertson HA
    Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.